Efficacy and Safety of Omalizumab in Patients With Severe Persistent Asthma

Sponsor
Novartis Pharmaceuticals
Study ID
NCT00046748
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to determine the effect of omalizumab, compared to placebo, on clinically significant asthma exacerbation rates in adolescents and adults with asthma.

Key Dates

Start date
Dec 31, 2001
Status verified
Jul 2017
Primary completion
Apr 30, 2004
Completion
Apr 30, 2004

Study Design

Enrollment
484 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Primary Outcome Measure

Clinically significant asthma exacerbation

Related Studies